"use client";
import Link from "next/link";
import Disclaimer from "@/components/Cvkd_disclaimer";

const CVKD = () => {
    const pressReleaseUrl = `https://stockverse.com/news/heart-disease-the-killer`; // The current URL

    const handleFacebookShare = () => {
        const facebookShareUrl = `https://www.facebook.com/sharer/sharer.php?u=${encodeURIComponent(
            pressReleaseUrl
        )}`;
        window.open(
            facebookShareUrl,
            "facebook-share-dialog",
            "width=626,height=436"
        );
    };

    // Function to share on Twitter
    const handleTwitterShare = () => {
        const twitterShareUrl = `https://twitter.com/share?url=${encodeURIComponent(
            pressReleaseUrl
        )}&text=Check%20out%20this%20press%20release!`;
        window.open(
            twitterShareUrl,
            "twitter-share-dialog",
            "width=626,height=436"
        );
    };

    // Function to share on LinkedIn
    const handleLinkedInShare = () => {
        const linkedInShareUrl = `https://www.linkedin.com/sharing/share-offsite/?url=${encodeURIComponent(
            pressReleaseUrl
        )}`;
        window.open(
            linkedInShareUrl,
            "linkedin-share-dialog",
            "width=626,height=436"
        );
    };

    // Function to share via Email
    const handleEmailShare = () => {
        const subject = "Check out this Press Release";
        const body = `I thought you might find this press release interesting: ${pressReleaseUrl}`;
        window.location.href = `mailto:?subject=${encodeURIComponent(
            subject
        )}&body=${encodeURIComponent(body)}`;
    };

    // Function to print the page
    const handlePrint = () => {
        window.print();
    };

    return (
        <>
            <div className="xl:container mx-auto sticky top-24 xl:px-10 px-3 py-4 w-full">
                <a
                    href="/dashboard?view=news"
                    className="font-MontserratMedium text-base 2xl:text-xl flex items-center w-max justify-start gap-4"
                >
                    <svg
                        className="w-5 h-5 text-gray-700"
                        viewBox="0 0 24 24"
                        fill="none"
                        stroke="currentColor"
                        strokeWidth="2"
                        strokeLinecap="round"
                        strokeLinejoin="round"
                    >
                        <path d="M19 12H5M12 19l-7-7 7-7" />
                    </svg>
                    Back to news
                </a>
            </div>
            <div className="w-full h-full mx-auto xl:container lg:px-[15%] max-xl:px-3">
                <div className="py-8 gap-y-6">
                    <h1 className="text-[#1D3045] font-MontserratSemibold md:text-4xl text-2xl !leading-[1.4]">
                    {`üíî Heart Disease: America‚Äôs Most Expensive Killer`}
                    </h1>
                </div>
                <div className="pt-8 lg:pt-4 flex flex-col sm:flex-row gap-y-6 justify-between items-start sm:items-center border-t border-[#404040]">
                    <Link
                        href="/dashboard?view=news"
                        className=" leading-[110%] text-base font-MontserratMedium text-[#634FF7]"
                    >
                        May, 2025 by Stockverse
                    </Link>
                    <div className="">
                        <p className="text-sm font-MontserratMedium  text-primaryText leading-[110%]">
                            SHARE THIS ARTICLE
                        </p>
                        <div className="flex flex-wrap items-center gap-2 pt-2">
                            <svg
                                onClick={handleFacebookShare}
                                className="cursor-pointer"
                                width="28"
                                height="28"
                                viewBox="0 0 32 32"
                                fill="none"
                                xmlns="http://www.w3.org/2000/svg"
                            >
                                <path
                                    d="M29.3334 21.5866C29.3334 26.44 26.4401 29.3333 21.5868 29.3333H20.0001C19.2667 29.3333 18.6667 28.7333 18.6667 28V20.3066C18.6667 19.9466 18.9601 19.64 19.3201 19.64L21.6667 19.6C21.8534 19.5866 22.0134 19.4533 22.0534 19.2666L22.5201 16.72C22.5601 16.48 22.3734 16.2533 22.1201 16.2533L19.2801 16.2933C18.9067 16.2933 18.6134 16 18.6001 15.64L18.5468 12.3733C18.5468 12.16 18.7201 11.9733 18.9467 11.9733L22.1467 11.92C22.3734 11.92 22.5468 11.7466 22.5468 11.52L22.4934 8.31995C22.4934 8.09328 22.3201 7.91996 22.0934 7.91996L18.4934 7.97331C16.2801 8.01331 14.5201 9.82662 14.5601 12.04L14.6268 15.7066C14.6401 16.08 14.3468 16.3733 13.9734 16.3866L12.3734 16.4133C12.1467 16.4133 11.9734 16.5866 11.9734 16.8133L12.0134 19.3466C12.0134 19.5733 12.1867 19.7466 12.4134 19.7466L14.0134 19.72C14.3868 19.72 14.6801 20.0133 14.6934 20.3733L14.8134 27.9733C14.8267 28.72 14.2267 29.3333 13.4801 29.3333H10.4134C5.56008 29.3333 2.66675 26.44 2.66675 21.5733V10.4133C2.66675 5.55996 5.56008 2.66663 10.4134 2.66663H21.5868C26.4401 2.66663 29.3334 5.55996 29.3334 10.4133V21.5866V21.5866Z"
                                    fill="black"
                                />
                            </svg>
                            <svg
                                onClick={handleLinkedInShare}
                                className="cursor-pointer"
                                width="28"
                                height="28"
                                viewBox="0 0 28 28"
                                fill="none"
                                xmlns="http://www.w3.org/2000/svg"
                            >
                                <path
                                    d="M18.6667 9.33331C20.5233 9.33331 22.3037 10.0708 23.6165 11.3836C24.9293 12.6963 25.6667 14.4768 25.6667 16.3333V24.5H21.0001V16.3333C21.0001 15.7145 20.7542 15.121 20.3167 14.6834C19.8791 14.2458 19.2856 14 18.6667 14C18.0479 14 17.4544 14.2458 17.0168 14.6834C16.5792 15.121 16.3334 15.7145 16.3334 16.3333V24.5H11.6667V16.3333C11.6667 14.4768 12.4042 12.6963 13.717 11.3836C15.0298 10.0708 16.8102 9.33331 18.6667 9.33331V9.33331Z"
                                    stroke="black"
                                    strokeWidth="2"
                                    strokeLinecap="round"
                                    strokeLinejoin="round"
                                />
                                <path
                                    d="M6.99992 10.5H2.33325V24.5H6.99992V10.5Z"
                                    stroke="black"
                                    strokeWidth="2"
                                    strokeLinecap="round"
                                    strokeLinejoin="round"
                                />
                                <path
                                    d="M4.66659 6.99998C5.95525 6.99998 6.99992 5.95531 6.99992 4.66665C6.99992 3.37798 5.95525 2.33331 4.66659 2.33331C3.37792 2.33331 2.33325 3.37798 2.33325 4.66665C2.33325 5.95531 3.37792 6.99998 4.66659 6.99998Z"
                                    stroke="black"
                                    strokeWidth="2"
                                    strokeLinecap="round"
                                    strokeLinejoin="round"
                                />
                            </svg>
                            <svg
                                onClick={handleTwitterShare}
                                className="cursor-pointer"
                                width="28"
                                height="28"
                                viewBox="0 0 32 32"
                                fill="none"
                                xmlns="http://www.w3.org/2000/svg"
                            >
                                <path
                                    d="M26.8088 11.5123C26.7769 11.2143 26.7396 10.9755 26.7089 10.8054L29.2215 7.03643C29.3795 6.79946 29.3695 6.4883 29.1966 6.26196C29.0237 6.03563 28.7262 5.94411 28.456 6.03417L24.9617 7.19891C24.7771 6.9235 24.5032 6.56022 24.1382 6.19522C23.3989 5.45589 22.2393 4.66663 20.6668 4.66663C19.0367 4.66663 17.8303 5.12287 16.9689 5.87189C16.1164 6.61322 15.6667 7.58488 15.4367 8.50494C15.207 9.42381 15.1865 10.3281 15.2197 10.9916C15.2294 11.1851 15.2437 11.3602 15.2593 11.5117C13.5858 11.8676 11.8346 11.3225 10.1192 10.3044C8.2276 9.18184 6.49361 7.55064 5.13819 6.19522C4.9502 6.00723 4.66849 5.94891 4.42132 6.0468C4.17414 6.14469 4.00875 6.38008 4.00045 6.6458C3.83058 12.0816 4.95125 18.661 10.015 21.9973C7.88515 23.1495 5.79696 23.6868 3.25076 24.0051C2.95925 24.0415 2.72596 24.2645 2.67636 24.5541C2.62676 24.8436 2.77255 25.1315 3.03531 25.2629C9.91358 28.702 18.8267 28.4535 23.8668 21.7333C25.9561 18.9475 26.6562 16.1545 26.8312 14.0553C26.9185 13.0069 26.8751 12.1307 26.8088 11.5123Z"
                                    fill="black"
                                />
                            </svg>
                            <svg
                                onClick={handleEmailShare}
                                className="cursor-pointer"
                                width="28"
                                height="28"
                                viewBox="0 0 28 28"
                                fill="none"
                                xmlns="http://www.w3.org/2000/svg"
                            >
                                <path
                                    d="M2.8292 6.36964C2.70097 6.58354 2.78709 6.85335 2.99914 6.98462L13.3857 13.4144C13.762 13.6473 14.2376 13.6473 14.6139 13.4144L25.0006 6.98451C25.2127 6.85323 25.2988 6.58341 25.1706 6.36951C24.559 5.34943 23.4425 4.66669 22.1666 4.66669H5.83325C4.55727 4.66669 3.44077 5.34949 2.8292 6.36964Z"
                                    fill="black"
                                />
                                <path
                                    d="M25.6666 10.2141C25.6666 9.82231 25.2365 9.58273 24.9034 9.78893L15.842 15.3984C14.7133 16.0971 13.2863 16.0971 12.1576 15.3984L3.09643 9.78909C2.76333 9.58289 2.33325 9.82247 2.33325 10.2142V19.8334C2.33325 21.7664 3.90025 23.3334 5.83325 23.3334H22.1666C24.0996 23.3334 25.6666 21.7664 25.6666 19.8334V10.2141Z"
                                    fill="black"
                                />
                            </svg>
                            <svg
                                onClick={handlePrint}
                                className="cursor-pointer"
                                width="28"
                                height="28"
                                viewBox="0 0 28 28"
                                fill="none"
                                xmlns="http://www.w3.org/2000/svg"
                            >
                                <path
                                    d="M23.9167 11.8883H20.5451C17.7801 11.8883 15.5284 9.63665 15.5284 6.87165V3.49998C15.5284 2.85831 15.0034 2.33331 14.3617 2.33331H9.41508C5.82175 2.33331 2.91675 4.66665 2.91675 8.83165V19.1683C2.91675 23.3333 5.82175 25.6666 9.41508 25.6666H18.5851C22.1784 25.6666 25.0834 23.3333 25.0834 19.1683V13.055C25.0834 12.4133 24.5584 11.8883 23.9167 11.8883Z"
                                    fill="black"
                                />
                                <path
                                    d="M6.41992 19V14.1H8.16992C8.43592 14.1 8.67626 14.1665 8.89092 14.2995C9.10792 14.4325 9.27942 14.611 9.40542 14.835C9.53142 15.059 9.59442 15.3051 9.59442 15.5735C9.59442 15.8488 9.52909 16.0985 9.39842 16.3225C9.27009 16.5441 9.09742 16.7215 8.88042 16.8545C8.66342 16.9851 8.42659 17.0505 8.16992 17.0505H7.27392V19H6.41992ZM7.27392 16.1965H8.07892C8.20026 16.1965 8.31109 16.1661 8.41142 16.1055C8.51176 16.0448 8.59109 15.9631 8.64942 15.8605C8.71009 15.7578 8.74042 15.6435 8.74042 15.5175C8.74042 15.3891 8.71009 15.2736 8.64942 15.171C8.59109 15.0683 8.51176 14.9866 8.41142 14.926C8.31109 14.8653 8.20026 14.835 8.07892 14.835H7.27392V16.1965Z"
                                    fill="white"
                                />
                                <path
                                    d="M10.2344 19V14.1H11.8584C12.1967 14.1 12.5129 14.1641 12.8069 14.2925C13.1032 14.4185 13.3634 14.5946 13.5874 14.821C13.8137 15.045 13.9899 15.3051 14.1159 15.6015C14.2442 15.8955 14.3084 16.2116 14.3084 16.55C14.3084 16.8883 14.2442 17.2056 14.1159 17.502C13.9899 17.796 13.8137 18.0561 13.5874 18.2825C13.3634 18.5065 13.1032 18.6826 12.8069 18.811C12.5129 18.937 12.1967 19 11.8584 19H10.2344ZM11.0884 18.146H11.8584C12.0754 18.146 12.2795 18.1051 12.4709 18.0235C12.6645 17.9395 12.8349 17.8251 12.9819 17.6805C13.1289 17.5335 13.2444 17.3643 13.3284 17.173C13.4124 16.9793 13.4544 16.7716 13.4544 16.55C13.4544 16.3283 13.4124 16.1218 13.3284 15.9305C13.2444 15.7391 13.1289 15.57 12.9819 15.423C12.8349 15.276 12.6657 15.1616 12.4744 15.08C12.283 14.996 12.0777 14.954 11.8584 14.954H11.0884V18.146Z"
                                    fill="white"
                                />
                                <path
                                    d="M14.876 19V14.1H17.7705V14.954H15.73V15.948H17.4345V16.802H15.73V19H14.876Z"
                                    fill="white"
                                />
                            </svg>
                        </div>
                    </div>
                </div>
                <div className="flex flex-col gap-6 py-4 2xl:pb-16 lg:pb-16 pb-8">
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">And the Public Company Quietly Developing a Potential Game-Changer</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                      Every 36 seconds, someone in the United States dies from heart disease. That adds up to over 2,300 deaths every single day. More than 121 million Americans are living with cardiovascular disease. Annual direct medical costs have surpassed $200 billion, burdening patients, families, and the healthcare system. Yet the most widely used blood thinner, <span className="font-bold">Warfarin</span>, has remained unchanged for more than 60 years.
                    </p>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]"> {`The Reality of Today‚Äôs Blood Thinners`}</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                      {`Warfarin has been prescribed for decades to reduce the risk of stroke, clotting, and other cardiovascular complications. But its limitations are widely known:`}
                    </p>
                    <ul className="list-disc font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48] space-y-6 ml-3">
                      <li>Requires frequent blood testing and dose adjustments</li>
                      <li>Interacts with common foods (especially those rich in Vitamin K)</li>
                      <li>Has dangerous drug-to-drug interactions</li>
                      <li>Carries a high risk of internal bleeding, including GI bleeds</li>
                      <li>Complicates treatment in elderly and kidney-impaired patients</li>
                    </ul>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                      {'Patients don‚Äôt choose Warfarin because it‚Äôs ideal ‚Äî they choose it because it‚Äôs the only FDA-approved option in many cases.'}
                    </p>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">The Unmet Medical Need</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                      {`Patients with implanted cardiac devices like Left Ventricular Assist Devices (LVADs) are particularly vulnerable. They require lifelong anticoagulation therapy ‚Äî yet Warfarin puts them at high risk of bleeding, especially when combined with chronic kidney disease.`}
                    </p>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                        {`This population has no oral anticoagulant currently approved specifically for their needs. The medical gap is urgent and growing.`}
                    </p>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">Introducing Cadrenal Therapeutics (CVKD)</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                        <span className="font-bold">Cadrenal Therapeutics (NASDAQ: CVKD)</span> is a clinical-stage biopharmaceutical company developing Tecarfarin, a novel oral blood thinner designed to address the limitations of Warfarin.
                    </p>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                      <span className="font-bold">Tecarfarin is a Vitamin K antagonist (VKA) like Warfarin</span> ‚Äî but with a key distinction: it‚Äôs metabolized by carboxyl esterase, not the liver‚Äôs cytochrome P450 system. This alternative metabolic pathway is being explored for its potential to offer greater stability, fewer interactions, and better suitability for patients with kidney or liver issues.
                    </p>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">{`Tecarfarin‚Äôs Potential Advantages`}</h4>
                    <ul className="list-disc font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48] space-y-6">
                      <li>Fewer food and drug interactions</li>
                      <li>Not dependent on kidney or liver function</li>
                      <li>More consistent therapeutic levels</li>
                      <li>Lower bleeding risk profile (pending trial outcomes)</li>
                      <li>Being developed for high-risk patients, including those with LVADs</li>
                    </ul>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                      {`Tecarfarin is being developed to potentially deliver the benefits of anticoagulation therapy with fewer of the complications commonly associated with older treatments like Warfarin.`}
                    </p>

                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">Latest Developments: Manufacturing & Trial Readiness</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                        {`On May 15, 2025, Cadrenal Therapeutics (CVKD) announced the successful completion of the technical transfer and U.S.-based manufacturing of Tecarfarin‚Äôs active pharmaceutical ingredient (API). This milestone is intended to strengthen the company‚Äôs supply chain and support readiness for upcoming pivotal trials.`}
                    </p>
                    <Link href="https://www.businesswire.com/news/home/20250515408603/en/Cadrenal-Therapeutics-Announces-Tecarfarin-Manufacturing-Progress-in-Support-of-Clinical-Trial-Readiness" className="underline font-MontserratBold">Read the full press release on BusinessWire</Link>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">
                    The company is preparing Tecarfarin for a Phase 3 clinical study, initially targeting two high-risk patient groups:
                    </p>
                    <ul className="list-disc font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48] space-y-6">
                      <li>Patients with implanted cardiac devices (LVADs)</li>
                      <li>Patients with end-stage kidney disease and atrial fibrillation</li>
                    </ul>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">If approved, Tecarfarin could become the first oral anticoagulant specifically indicated for these populations.</p>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">Analyst Coverage: ‚ÄúBuy‚Äù Rating Reaffirmed</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">{`In May 2025, H.C. Wainwright & Co. reiterated a Buy rating on CVKD, issuing a price target of $32, citing Tecarfarin‚Äôs differentiated profile, market potential, and advancing clinical pipeline.`}</p>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">{`‚ÄúWe believe CVKD‚Äôs progress on manufacturing and trial planning, combined with Tecarfarin‚Äôs unique mechanism, supports a favorable risk-reward ratio for long-term investors.‚Äù ‚Äî H.C. Wainwright Equity Research (May 2025)`}</p>
                    <Link href="https://www.gurufocus.com/news/2869695/cadrenal-therapeutics-cvkd-receives-buy-rating-from-hc-wainwright-co-cvkd-stock-news" className="underline font-MontserratBold">üìÑ Read the full analyst coverage on GuruFocus</Link>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">Why Investors Are Watching CVKD</h4>
                    <table className="text-left font-MontserratMedium text-sm">
                      <tr className="border-b">
                        <th>Strategic Factor</th>
                        <th>Why It Matters</th>
                      </tr>
                      <tr className="border-b">
                        <td className="py-3">FDA Orphan Drug Status</td>
                        <td className="py-3">Creates exclusive market rights and accelerates the process</td>
                      </tr>
                      <tr className="border-b">
                        <td className="py-3">Large, underserved market	</td>
                        <td>High-risk patients need alternatives now</td>
                      </tr>
                      <tr className="border-b">
                        <td className="py-3">Platform potential</td>
                        <td className="py-3">Could extend beyond LVADs into other cardiac segments</td>
                      </tr>
                      <tr className="border-b">
                        <td className="py-3">First-mover advantage	</td>
                        <td className="py-3">No oral blood thinner is currently approved for LVAD patients</td>
                      </tr>
                      <tr className="border-b">
                        <td className="py-3">Public listing</td>
                        <td className="py-3">Ticker: CVKD (accessible on the open market)</td>
                      </tr>
                    </table>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">CVKD is positioned at the intersection of medical innovation and patient need. For investors seeking early-stage exposure to potential breakthroughs in cardiovascular care, this is a company to watch closely.</p>
                    <h4 className="text-[#1D3045] font-MontserratBold pt-24 2xl:text-4xl text-2xl !leading-[1.5]">About the Company</h4>
                    <ul className="list-disc font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48] space-y-6">
                      <li><span className="font-MontserratBold">Company:</span> Cadrenal Therapeutics, Inc.</li>
                      <li><span className="font-MontserratBold">Ticker: </span> CVKD</li>
                      <li><span className="font-MontserratBold">Exchange:</span> NASDAQ</li>
                      <li><span className="font-MontserratBold">Sector:</span> Biopharmaceuticals</li>
                      <li><span className="font-MontserratBold">Focus:</span> Cardiovascular therapies, next-generation anticoagulation</li>
                      <li className="font-MontserratBold">Website: <Link href="" className="underline">www.cadrenal.com</Link></li>
                    </ul>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-4 text-[#343D48]">Sponsored Content Disclosure: This content is part of a paid awareness campaign. Please read the full disclaimer below.</p>
                    <h4 className="font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48]">Enjoyed This Article?</h4>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-4 text-[#343D48]">If you found this breakdown of Cadrenal Therapeutics (CVKD) helpful, we invite you to join Stockverse ‚Äî a platform built for investors who want early access to unique stock insights before they hit the mainstream.</p>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-4 text-[#343D48]">Sign up today to access:</p>
                    <ul className="list-disc font-MontserratMedium text-base 2xl:text-xl pt-12 text-[#343D48] space-y-6">
                      <li>Exclusive alerts on stocks like <span className="font-MontserratBold">CVKD</span></li>
                      <li>Real-time news and technical data</li>
                      <li>Watchlist tools and portfolio tracking</li>
                      <li>Deep-dive research on emerging growth companies</li>
                      <li><span className="font-MontserratBold">Focus:</span> Cardiovascular therapies, next-generation anticoagulation</li>
                      <li className="font-MontserratBold">Website: <Link href="www.cadrenal.com" className="underline">www.cadrenal.com</Link></li>
                    </ul>
                    <p className="font-MontserratMedium text-base 2xl:text-xl pt-4 text-[#343D48]">üëâ Register now at <Link href="Stockverse.com/register" className="font-MontserratBold underline">Stockverse.com/register</Link><br/>Join the community. Stay informed. Stay ahead.</p>
                </div>
                <Disclaimer />
            </div>
        </>
    );
};

export default CVKD;